GlassScriptPhysician profile
Pamela B Egan
NPI 1700088788
$14,552.60
in general payments reported to CMS, 2019-2025
57 companies · $3,590 in 2025
The $3,590 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,849 · 2022: $2,709 · 2023: $3,379 · 2024: $3,026 · 2025: $3,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,961 · Education: $23.35 · Gift: $10.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,961.00 |
| Education | $23.35 |
| Gift | $10.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,165.77 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,454.46 | 2021-2025 | |
| Novo Nordisk INC | $1,327.81 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $641.01 | 2022-2025 | Caplyta |
| Amgen INC. | $491.85 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.18 | 2023-2025 | Jardiance, Tradjenta |
| Gilead Sciences, INC. | $388.83 | 2021-2024 | Epclusa |
| Bayer Healthcare Pharmaceuticals INC. | $375.44 | 2022-2025 | |
| Lilly USA, LLC | $354.26 | 2021-2024 | Zepbound, Jardiance, Mounjaro |
| Amarin Pharma, INC. | $324.00 | 2021-2023 | |
| Neurelis, INC. | $319.38 | 2022-2024 | Valtoco |
| Antares Pharma, INC. | $319.23 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Qol Medical, LLC | $315.93 | 2022-2025 | Sucraid, Sucraid |
| Astellas Pharma US INC | $311.18 | 2023-2025 | Veozah, Cresemba, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $294.29 | 2022 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $290.45 | 2021-2023 | Trelegy Ellipta |
| Dexcom, INC. | $255.43 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Idorsia Pharmaceuticals US INC | $253.06 | 2023-2025 | Quviviq, Quviviq |
| Alexion Pharmaceuticals, INC. | $244.69 | 2023 | |
| Sanofi-Aventis U.S. LLC | $242.39 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.96 | 2022-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $214.99 | 2024-2025 | Voquezna |
| Tolmar, INC. | $189.38 | 2023-2025 | Jatenzo |
| Inspire Medical Systems, INC. | $185.32 | 2024-2025 | Inspire |
| Ascend Therapeutics US, LLC | $159.21 | 2022-2023 | |
| Currax Pharmaceuticals LLC | $158.44 | 2021-2025 | Contrave, Onzetra Xsail |
| Esperion Therapeutics, INC. | $155.20 | 2024-2025 | Nexletol, Nexlizet |
| Exact Sciences Corporation | $154.09 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Daiichi Sankyo INC. | $150.86 | 2021-2025 | Enhertu |
| Abbott Laboratories | $145.53 | 2024-2025 | Freestyle Libre 3, Freestyle Libre |
| Edwards Lifesciences Corporation | $141.55 | 2025 | |
| Intercept Pharmaceuticals, INC. | $125.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.57 | 2023 | Camzyos |
| Actelion Pharmaceuticals US, INC. | $121.69 | 2024 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $115.00 | 2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $114.99 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $106.82 | 2024 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $106.05 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $100.00 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $100.00 | 2021 | |
| Merck Sharp & Dohme LLC | $97.37 | 2023 | Verquvo |
| Ardelyx, INC. | $88.83 | 2025 | Ibsrela |
| Pfizer INC. | $85.16 | 2021-2025 | |
| Millicent US INC | $75.68 | 2021-2025 | Intrarosa, Femring, Femlyv |
| Azurity Pharmaceuticals, INC. | $68.42 | 2023-2024 | Adthyza, Edarbi |
| Acella Pharmaceuticals, LLC | $67.66 | 2022-2025 | NP Thyroid 60 |
| Halozyme INC | $60.87 | 2023 | |
| Clarus Therapeutics INC. | $57.21 | 2021 | |
| Avion Pharmaceuticals | $51.23 | 2021-2023 | Balcoltra |
| Virtus Pharmaceuticals LLC | $49.39 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $38.16 | 2022-2023 | Nascobal |
| Acerus Pharmaceuticals Corporation | $30.95 | 2021-2022 | |
| Alfasigma USA, INC. | $30.93 | 2022 | |
| Atland Pharmaceuticals, LLC | $29.64 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Novartis Pharmaceuticals Corporation | $23.07 | 2024 | |
| Pharmacosmos Therapeutics INC. | $20.91 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.